End-of-treatment HBcrAg and HBsAb levels identify durable functional cure after Peg-IFN-based therapy in patients with CHB. Huang D, Wu D, Wang P, Wang Y, et al. J Hepatol 2022;77:42-54.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Huang D, Wu D, Wang P, Wang Y, et al. End-of-treatment HBcrAg and HBsAb levels identify durable functional cure after Peg-IFN-based therapy in patients with CHB. J Hepatol 2022;77:42-54.
PMID: 35149125